Primary sterile necrotic cells fail to cross-prime CD8+ T cells

OncoImmunology

Volumn 1, Issue 7, 2012, Pages 1017-1026

  Gamrekelashvili, Jaba ^a,b   Ormandy, Lars A ^b,c   Heimesaat, Markus M ^d   Kirschning, Carsten J ^e   Manns, Michael P ^b   Korangy, Firouzeh ^a   Greten, Tim F ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Cancer vaccine; CD8+ T cells; Cross priming; Death; Sterile necrosis; Tumor cells

Indexed keywords

B7 ANTIGEN; CANCER NECROTIC CELL VACCINE; CANCER VACCINE; CD40 ANTIGEN; CD86 ANTIGEN; DOUBLE STRANDED DNA; GAMMA INTERFERON; GLYCOPROTEIN P 15095; LIVE VACCINE; MYELOID DIFFERENTIATION FACTOR 88; OVALBUMIN; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELL DEATH; CELLULAR IMMUNITY; CONTROLLED STUDY; CPG ISLAND; CROSS PRESENTATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; ELECTROPORATION; FEMALE; IMMUNOGENICITY; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PRIMARY STERILE NECROTIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

EID: 84881668702     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21098     Document Type: Article

References (56)

1. Ma Y, Conforti R, Aymeric L, Locher C, Kepp O, Kroemer G, et al. How to improve the immunogenicity of chemotherapy and radiotherapy. Cancer Metastasis Rev 2011; 30:71-82; PMID:21298323; http://dx.doi. org/10.1007/s10555-011-9283-2.
2. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999; 5:1249-55; PMID:10545990; http:// dx.doi.org/10.1038/15200.
3. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12:991-1045; PMID:8011301; http://dx.doi.org/10.1146/annurev. iy.12.040194.005015.
4. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000; 191:423-34; PMID:10662788; http://dx.doi. org/10.1084/jem.191.3.423.
5. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 2000; 12:1539-46; PMID:11058573; http://dx.doi.org/10.1093/intimm/12.11.1539.
6. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418:191-5; PMID:12110890; http://dx.doi.org/10.1038/nature00858.
7. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425:516-21; PMID:14520412; http://dx.doi.org/10.1038/nature01991.
8. Ishii KJ, Suzuki K, Coban C, Takeshita F, Itoh Y, Matoba H, et al. Genomic DNA released by dying cells induces the maturation of APCs. J Immunol 2001; 167:2602-7; PMID:11509601.
9. Karikó K, Ni H, Capodici J, Lamphier M, Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 2004; 279:12542-50; PMID:14729660; http://dx.doi.org/10.1074/jbc.M310175200.
10. Lee J, Chuang TH, Redecke V, She L, Pitha PM, Carson DA, et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci U S A 2003; 100:6646-51; PMID:12738885; http:// dx.doi.org/10.1073/pnas.0631696100.
11. Wilkin F, Duhant X, Bruyns C, Suarez-Huerta N, Boeynaems JM, Robaye B. The P2Y11 receptor mediates the ATP-induced maturation of human monocytederived dendritic cells. J Immunol 2001; 166:7172-7; PMID:11390464.
12. Ahrens S, Zelenay S, Sancho D, Hanc P, Kjaer S, Feest C, et al. F-actin is an evolutionarily conserved damageassociated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity 2012; 36:635-45; PMID:22483800; http://dx.doi.org/10.1016/j.immuni. 2012.03.008.
13. Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005; 11:1173-9; PMID:16244651; http://dx.doi.org/10.1038/nm1315.
14. Woo M, Hakem R, Mak TW. Executionary pathway for apoptosis: lessons from mutant mice. Cell Res 2000; 10:267-78; PMID:11191349; http://dx.doi. org/10.1038/sj.cr.7290054.
15. Joza N, Kroemer G, Penninger JM. Genetic analysis of the mammalian cell death machinery. Trends Genet 2002; 18:142-9; PMID:11858838; http://dx.doi. org/10.1016/S0168-9525(01)02618-X.
16. Liu K, Iyoda T, Saternus M, Kimura Y, Inaba K, Steinman RM. Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med 2002; 196:1091-7; PMID:12391020; http://dx.doi. org/10.1084/jem.20021215.
17. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392:86-9; PMID:9510252; http://dx.doi.org/10.1038/32183.
18. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumorspecific CD8 T cells. J Immunol 2003; 170:4905-13; PMID:12734333.
19. Janssen E, Tabeta K, Barnes MJ, Rutschmann S, McBride S, Bahjat KS, et al. Efficient T cell activation via a Toll-Interleukin 1 Receptor-independent pathway. Immunity 2006; 24:787-99; PMID:16782034; http:// dx.doi.org/10.1016/j.immuni.2006.03.024.
20. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202:1691-701; PMID:16365148; http://dx.doi.org/10.1084/jem.20050915.
21. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15:1170-8; PMID:19767732; http://dx.doi.org/10.1038/ nm.2028.
22. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54-61; PMID:17187072; http://dx.doi. org/10.1038/nm1523.
23. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell 2011; 147:728-41; PMID:22078875; http://dx.doi.org/10.1016/j. cell.2011.10.026.
24. Uhl M, Kepp O, Jusforgues-Saklani H, Vicencio JM, Kroemer G, Albert ML. Autophagy within the antigen donor cell facilitates efficient antigen cross-priming of virus-specific CD8+ T cells. Cell Death Differ 2009; 16:991-1005; PMID:19229247; http://dx.doi. org/10.1038/cdd.2009.8.
25. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334:1573-7; PMID:22174255; http://dx.doi.org/10.1126/science. 1208347.
26. Hirt UA, Leist M. Rapid, noninflammatory and PS-dependent phagocytic clearance of necrotic cells. Cell Death Differ 2003; 10:1156-64; PMID:14502239; http://dx.doi.org/10.1038/sj.cdd.4401286.
27. Brouckaert G, Kalai M, Krysko DV, Saelens X, Vercammen D, Ndlovu MN, et al. Phagocytosis of necrotic cells by macrophages is phosphatidylserine dependent and does not induce inflammatory cytokine production. Mol Biol Cell 2004; 15:1089-100; PMID:14668480; http://dx.doi.org/10.1091/mbc. E03-09-0668.
28. Scheffer SR, Nave H, Korangy F, Schlote K, Pabst R, Jaffee EM, et al. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J Cancer 2003; 103:205-11; PMID:12455034; http:// dx.doi.org/10.1002/ijc.10777.
29. Gamrekelashvili J, Krüger C, von Wasielewski R, Hoffmann M, Huster KM, Busch DH, et al. Necrotic tumor cell death in vivo impairs tumor-specific immune responses. J Immunol 2007; 178:1573-80; PMID:17237406.
30. Somersan S, Larsson M, Fonteneau JF, Basu S, Srivastava P, Bhardwaj N. Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J Immunol 2001; 167:4844-52; PMID:11673488.
31. Salio M, Cerundolo V, Lanzavecchia A. Dendritic cell maturation is induced by mycoplasma infection but not by necrotic cells. Eur J Immunol 2000; 30:705-8; PMID:10671230; http://dx.doi.org/10.1002/1521-4141(200002)30:2<705::AID-IMMU705>3 .0.CO;2- P.
32. Singh-Jasuja H, Scherer HU, Hilf N, Arnold-Schild D, Rammensee HG, Toes RE, et al. The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. Eur J Immunol 2000; 30:2211-5; PMID:10940912.
33. Vabulas RM, Braedel S, Hilf N, Singh-Jasuja H, Herter S, Ahmad-Nejad P, et al. The endoplasmic reticulumresident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem 2002; 277:20847-53; PMID:11912201; http://dx.doi. org/10.1074/jbc.M200425200.
34. Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD, Wagner H. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem 2002; 277:15107-12; PMID:11842086; http:// dx.doi.org/10.1074/jbc.M111204200.
35. Shi Y, Zheng W, Rock KL. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc Natl Acad Sci U S A 2000; 97:14590-5; PMID:11106387; http://dx.doi.org/10.1073/ pnas.260497597.
36. Sancho D, Joffre OP, Keller AM, Rogers NC, Martínez D, Hernanz-Falcón P, et al. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature 2009; 458:899-903; PMID:19219027; http://dx.doi.org/10.1038/nature07750.
37. Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 2002; 8:1974-83; PMID:12060643.
38. den Brok MH, Sutmuller RP, Nierkens S, Bennink EJ, Frielink C, Toonen LW, et al. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer 2006; 95:896-905; PMID:16953240; http://dx.doi.org/10.1038/ sj.bjc.6603341.
39. den Brok MH, Sutmuller RP, Nierkens S, Bennink EJ, Toonen LW, Figdor CG, et al. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. Cancer Res 2006; 66:7285-92; PMID:16849578; http://dx.doi. org/10.1158/0008-5472.CAN-06-0206.
40. Norbury CC, Basta S, Donohue KB, Tscharke DC, Princiotta MF, Berglund P, et al. CD8+ T cell crosspriming via transfer of proteasome substrates. Science 2004; 304:1318-21; PMID:15166379; http://dx.doi. org/10.1126/science.1096378.
41. Lev A, Takeda K, Zanker D, Maynard JC, Dimberu P, Waffarn E, et al. The exception that reinforces the rule: crosspriming by cytosolic peptides that escape degradation. Immunity 2008; 28:787-98; PMID:18549799; http://dx.doi.org/10.1016/j.immuni.2008.04.015.
42. Kurts C, Miller JF, Subramaniam RM, Carbone FR, Heath WR. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med 1998; 188:409-14; PMID:9670054; http://dx.doi.org/10.1084/jem.188.2.409.
43. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001; 19:47-64; PMID:11244030; http://dx.doi. org/10.1146/annurev.immunol.19.1.47.
44. Li M, Davey GM, Sutherland RM, Kurts C, Lew AM, Hirst C, et al. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol 2001; 166:6099-103; PMID:11342628.
45. Yewdell JW. The seven dirty little secrets of major histocompatibility complex class I antigen processing. Immunol Rev 2005; 207:8-18; PMID:16181323; http://dx.doi.org/10.1111/j.0105-2896.2005.00309.x.
46. de Brito C, Tomkowiak M, Ghittoni R, Caux C, Leverrier Y, Marvel J. CpG promotes cross-presentation of dead cell-associated antigens by pre-CD8a+ dendritic cells [corrected]. J Immunol 2011; 186:1503-11; PMID:21187449; http://dx.doi. org/10.4049/jimmunol.1001022.
47. Silagi S. Control of pigment production in mouse melanoma cells in vitro. Evocation and maintenance. J Cell Biol 1969; 43:263-74; PMID:4981070; http:// dx.doi.org/10.1083/jcb.43.2.263.
48. Klein C, Bueler H, Mulligan RC. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med 2000; 191:1699-708; PMID:10811863; http://dx.doi. org/10.1084/jem.191.10.1699.
49. Clarke SR, Barnden M, Kurts C, Carbone FR, Miller JF, Heath WR. Characterization of the ovalbuminspecific TCR transgenic line OT-I: MHC elements for positive and negative selection. Immunol Cell Biol 2000; 78:110-7; PMID:10762410; http://dx.doi. org/10.1046/j.1440-1711.2000.00889.x.
50. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994; 76:17-27; PMID:8287475; http://dx.doi.org/10.1016/0092-8674(94)90169-4.
51. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408:740-5; PMID:11130078; http://dx.doi.org/10.1038/35047123.
52. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999; 162:3749-52; PMID:10201887.
53. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999; 11:443-51; PMID:10549626; http://dx.doi.org/10.1016/S1074-7613(00)80119-3.
54. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 1998; 9:143-50; PMID:9697844; http://dx.doi.org/10.1016/S1074-7613(00)80596-8.
55. Spiller S, Dreher S, Meng G, Grabiec A, Thomas W, Hartung T, et al. Cellular recognition of trimyristoylated peptide or enterobacterial lipopolysaccharide via both TLR2 and TLR4. J Biol Chem 2007; 282:13190-8; PMID:17353199; http://dx.doi.org/10.1074/jbc. M610340200.
56. Oehen S, Brduscha-Riem K. Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. J Immunol 1998; 161:5338-46; PMID:9820507.